<DOC>
	<DOCNO>NCT01921868</DOCNO>
	<brief_summary>The purpose study learn treatment acetyl-L-carnitine ( ALCAR ) affect hearts patient Friedreich 's Ataxia well may affect symptom Friedreich 's Ataxia difficulty balance , walk , upper arm function .</brief_summary>
	<brief_title>An Open-label Study Effects Acetyl-L-Carnitine Cardiovascular Outcomes Friedreich 's Ataxia</brief_title>
	<detailed_description>This study open label , pilot study ALCAR subject FA . In study 20 patient FA receive ALCAR every day 24 month . At study endpoint , subject assess change cardiovascular outcome FA symptom . To determine effect LC change cardiomyopathy , echocardiography strain rate calculate . This technique validate clinical study use study FA patient comparison regional deformation myocardial wall thickness .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>1 . Outpatients Friedreich 's Ataxia diagnose movement disorder specialist confirm genetic testing ( patient first degree relative patient ) . Subject may nonambulatory . 2 . Age 18 year 80 year . 3 . Stable medical condition 3 month prior screen . 4 . Women childbearing potential must use reliable method contraception must provide negative pregnancy test entry study . 5 . If cardiac medication betablockers ace inhibitor , patient must stable dose 6 month prior study entry duration study . 6 . Friedreich 's Ataxia patient systolic diastolic dysfunction present echocardiogram ejection fraction 35 % 65 % screening . 7 . Subjects ejection fraction &lt; 50 % need stable optimal heart failure therapy least 2 week prior screen . 1 . Any unstable illness concomitant medical condition , investigator 's opinion , preclude participation study . This include disorder may affect gait balance ( stroke , arthritis , etc ) . 2 . Pregnancy lactation . 3 . Concurrent participation another clinical study use investigational product use . Subjects currently enrol Friedreich 's Ataxia Clinical Outcome Measures Study site allow enroll study well . 4 . Any use investigational product within past 30 day . 5 . Dementia psychiatric illness prevents patient give informed consent ( Mini Mental Status Exam score less 25 ) . 6 . Legal incapacity limit legal capacity . 7 . History stroke . 8 . Subjects history thyroid disease ( hypothyroidism ) . Clinical laboratory evaluation thyroid stimulate hormone level take 3 month prior study screen use confirm absence current thyroid problem . 9 . Subjects history seizure . 10 . Subjects take warfarin acenocoumarol . 11 . Presence severe renal disease ( estimate creatinine clearance &lt; 50 mL/min ) hepatic disease ( AST Alanine transaminase ( ALT ) &gt; 2x time normal ) ( evidence lab report within past 6 month ) . 12 . Clinically significantly abnormal white blood cell , hemoglobin platelet count ( evidence lab report within past 6 month ) . 13 . Subjects blood work show carnitine deficiency ( &lt; 60nmol/mg total carnitine urine &lt; 35umol/L total carnitine plasma ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>